ATG16L1 T300A increases risk of Crohn's disease.

The association between the ATG16L1 rs2241880 (T300A) polymorphism and Crohn’s disease (CD) is one of the most robust findings in inflammatory bowel disease (IBD) genetics. This variant involves a single nucleotide polymorphism (SNP) that replaces threonine with alanine at position 300, significantly altering the cellular response to intestinal stress.

Clinical and genetic evidence

Extensive meta-analyses have established the T300A variant (G allele) as a major susceptibility factor for Crohn’s disease.

• Effect Size: Large-scale studies involving tens of thousands of participants show that the G allele consistently increases CD risk with an odds ratio (OR) ranging from 1.23 to 1.33 (p < 0.001).
• Population Consistency: This association is robust across diverse populations, particularly in European and North American cohorts, and has been replicated in pediatric-onset CD populations.
• Disease Specificity: The risk is specific to Crohn’s disease, with no significant association typically found with ulcerative colitis, highlighting a distinct genetic architecture for CD pathogenesis related to autophagy.

Mechanistic explanations

The T300A variant drives disease through a specific molecular mechanism that compromises the gut's defense systems.

• Structural Impact: The substitution of alanine for threonine creates a more rigid protein structure. This rigidity prevents caspase-3-mediated cleavage at the Thr300 site, which is necessary for the proper regulation of ATG16L1 during cellular stress.
• Autophagy and Xenophagy: While the variant does not abolish all autophagy, it specifically impairs xenophagy—the process of identifying and clearing intracellular pathogens.
• Paneth Cell Dysfunction: The defect is most pronounced in Paneth cells of the small intestine. T300A leads to abnormal granule morphology and impaired exocytosis, which reduces the secretion of critical antimicrobial peptides like alpha-defensins.
• Inflammatory Cascade: This defect in pathogen clearance and antimicrobial defense triggers hypersecretion of IL-1β and activation of NF-κB pathways, creating a state of chronic, microbiota-driven inflammation.

Bottom line

The ATG16L1 rs2241880 (T300A) variant is a validated risk factor for Crohn's disease. It increases susceptibility by approximately 23–33% through a mechanism involving impaired autophagy and Paneth cell dysfunction, which weakens the intestinal barrier and promotes chronic inflammation.